Great work Team Ardelyx! Our team walked over 11,500,00 steps in the International Foundation for Gastrointestinal Disorders (IFFGD)'s Virtual Digestive Health Wellness & Walk Event! We're proud to step up and help raise awareness for the #GI community. #ArdelyxProud
Ardelyx, Inc.
Biotechnology Research
Waltham, MA 14,308 followers
Translating Scientific Breakthroughs into Promise for Patients
About us
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3
- Website
-
http://www.ardelyx.com
External link for Ardelyx, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Waltham, MA
- Type
- Public Company
- Founded
- 2007
Locations
-
Primary
400 Fifth Avenue
210
Waltham, MA 02451, US
-
34175 Ardenwood Blvd
Fremont, CA 94555, US
-
260 E Highland Ave
Milwaukee, Wisconsin 53202, US
Employees at Ardelyx, Inc.
Updates
-
At Ardelyx, we challenge convention to bring innovation to patients. Learn how you can join the team at: https://bit.ly/4aVLFwc #careers #biotech
-
Save the date! We will present second quarter 2024 financial results and provide a business update on Thursday, August 1 at 4:30 PM ET via live webcast and conference call. Learn more: https://bit.ly/3WtndOL $ARDX
-
Press Release: Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines. Click to read: https://bit.ly/4f6vFdW
-
Make sure to join the Dialysis Patient Citizens Education Center as they go live on Instagram for a "Discussion on Phosphorus" on July 17th at 12:30PM ET. Set a reminder for the event here: https://bit.ly/3L9Qdo7 #kidneydisease
-
-
Today we announced that in an effort to preserve patient access to XPHOZAH, we have chosen not to apply for inclusion in the Centers for Medicare & Medicaid Services End-Stage Renal Disease Prospective Payment System Transitional Drug Add-on Payment Adjustment. Learn more: https://lnkd.in/eSWG59bn
-
-
Where will Team Ardelyx be this month? We have a whole new round up of #GI and #kidneydisease conferences we'll be attending!
-
Johannah Ruddy M.Ed, our director of patient advocacy, shares why she's proud to be part of a team that is committed to celebrating differences and embracing diversity! #ArdelyxProud #PrideMonth 🌈
-